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Binding proteinMutations in cereblon (CRBN), a substrate binding component of the E3 ubiquitin ligase complex, cause a form
of mental retardation in humans. However, the cellular proteins that interact with CRBN remain largely
unknown. Here, we report that CRBN directly interacts with the α1 subunit of AMP-activated protein kinase
(AMPK α1) and inhibits the activation of AMPK activation. The ectopic expression of CRBN reduces
phosphorylation of AMPK α1 and, thus, inhibits the enzyme in a nutrient-independent manner. Moreover,
AMPK α1 can be potently activated by suppressing endogenous CRBN using CRBN-speciﬁc small hairpin
RNAs. Thus, CRBN may act as a negative modulator of the AMPK signaling pathway in vivo.+82 62 715 2484.
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In humans, the cereblon gene has been linked to autosomal
recessive nonsyndromic mental retardation (ARNSMR) [1]. CRBN was
initially characterized as an RGS-containing novel protein that acted
as a K+ channel-interacting protein in the rat brain [2], and was later
shown to interact with a voltage-gated chloride channel (CIC) in the
retina [3]. CRBN inhibits the assembly and surface expression of the
large-conductance Ca2+-activated K+ channelα subunit [2]. Recently,
CRBN was shown to be the primary target of thalidomide induced
teratogenicity and a substrate binding component for the E3-
ubiquitin ligase [4]. Despite the association of CRBN to the afore-
mentioned proteins, the molecular characteristics of CRBN and its
cellular functions have not been well deﬁned.
To elucidate the cellular functions of CRBN, we searched for CRBN
binding partners in rat brain and found a direct interaction between
the α1 subunit of AMP-activated protein kinase (AMPK α1) and
CRBN. AMPK, a master sensor of energy balance, inhibits ATP-
consuming anabolic pathways and increases ATP-producing catabolic
pathways [5,6]. AMPK is a serine/threonine protein kinase made up of
a heterotrimer of a catalytic α subunit and two regulatory subunits
(β and γ) [7]. The α subunit contains three different domains: the
catalytic domain, the autoinhibitory domain (AID) and the β-subunit
binding domain [8]. The β subunit contains a glycogen-binding
domain and the γ subunit contains four cystathionine-β-synthase
(CBS) motifs. Of the four CBS motifs present in mammalian γ subunit,
two bind AMP/ATP interchangeably (Sites 1 and 3), Site 4 binds AMPnon-exchangeably and Site 2 does not bind nucleotide [8,9]. AMPK
can be activated by phosphorylation on Thr172 by upstream kinases
such as AMPK kinase (AMPKK) [6,10,11]. The β subunit functions as a
scaffold for the α and γ subunits, and targets the complex to
intracellular sites such as the plasma membrane after myristoylation
of its N terminus [12,13] and to intracellular glycogen stores through
its glycogen-binding domain [14]. Recently, protein crystallography
showed that the C-terminal region of the β subunit of AMPK was
important in mediating the interaction between the α and γ subunits
[9,15,16]. Although AMPK is thought to play important roles in certain
diseases such as diabetes, obesity, and stroke, the protein regulators of
this enzyme are poorly understood [17–22]. In this study, we
investigated the interaction between CRBN and AMPK, and the effects
of CRBN on the functional activity of AMPK.
2. Materials and methods
2.1. Yeast two-hybrid screen
Rat CRBN (rCRBN)was used as bait to screen a rat brain cDNA library
(Clontech, Palo Alto, CA). The full-length cDNA encoding rCRBN was
subcloned into pGBK-T7, a Gal4 DNA-binding vector (BD Biosciences,
San Jose, CA), using standard protocols. Stable expression of the bait
protein in yeast strainAH109was conﬁrmedby immunoblotting using a
mouse monoclonal antibody (mAb) speciﬁc for the GAL4 DNA-binding
domain (Santa Cruz Biotechnology, Santa Cruz, CA). Library scale
screening was performed on ~3 million co-transformants according to
the manufacturer's instructions. A rat brain cDNA library was cloned
into theGAL4 activation-domain vector pACT2 (BDBiosciences) and co-
transformed into the yeast AH109 with the bait clone using the Li+-
acetate method. Co-transformants were plated and selected on triple-
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growing on the triple-negative medium were further selected on
quadruple-negative medium (SD/TrpLeuHisAdenine, containing 1 mM
3-amino-1,2,4-trizole (3-AT)). In order to conﬁrm initial positives,
clones surviving on the quadruple-negative medium were retrans-
formed with the bait vector. Subsequently, the DNA sequences of the
conﬁrmed positive clones were determined using the dideoxy chain
termination sequencing method.
2.2. Cell culture and transfection
The HEK293FT, SH-SY5Y, HT22, and B103 cell lines were cultured in
Dulbecco's modiﬁed Eagle's medium (DMEM, GIBCO) with 10% (v/v)
fetal bovine serum (FBS, Hyclone). Cells were transfected using either
LipofectAMINETM LTX (GIBCO) or PolyfectTM (Qiagen, Valencia, CA)
according to the manufacturer's protocol.
2.3. Construction and generation of CRBN knockdown cell lines
In order to establish CRBN knockdown cells, lentiviral delivery of a
short hairpin RNA (shRNA) was used. The MISSIONTM TRC shRNA set,
cloned into the pLKO-puro vector (TRCN0000113340-44), was
purchased from Sigma. Lentiviral particles were generated and
concentrated to 107 TU/μl (Macrogen, South Korea). HT22 cells
infected with virus were selected and maintained using 10 μg/ml
puromycin in the medium for 4 weeks, and down-regulation of
endogenous CRBN was conﬁrmed by Western blot analysis.
2.4. Site-directed mutagenesis of AMPK α1
A constitutively active mutant (1-548, T172D) and an inactive
mutant of AMPK α1 (1-548, D157A) were generated by two
sequential polymerase chain reactions using mutagenic primers.
Synthetic oligonucleotides were obtained from Cosmo Genetech
(Seoul, Korea). To conﬁrm the authenticity of the DNA sequence of
each mutant, all constructs were sequenced and/or restriction
enzyme digested.
2.5. Western blot analysis
Proteins were separated by SDS-PAGE and blotted onto polyvinyli-
dene ﬂuoride (PVDF) membranes. After blocking with 3% BSA in TBS-T
(137 mM NaCl, 20 mM Tris–Cl, pH 7.6, 0.1% Tween 20), the blots were
incubated with various primary antibodies: rabbit polyclonal anti-
AMPKα1 (Epitomics, Burlingame, CA), rabbit polyclonal anti-phospho-
AMPK α1 (Cell Signaling), rabbit polyclonal anti-AMPK β (Cell
signaling), rabbit polyclonal anti-AMPK γ1 (C-terminus) (Epitomics),
mouse monoclonal anti-Myc (Upstate), rat monoclonal anti-HA
(Roche), rabbit polyclonal anti-ACC (Cell Signaling), or rabbit polyclonal
anti-phospho-ACC (Cell Signaling). The generation of rabbit polyclonal
anti-CRBN antibody against rat CRBNwas described in a previous report
[2] and its immunoreactivity with human and mouse CRBN was
conﬁrmed (Supplemental Fig. 1). The blots were then incubated with
horseradish peroxidase (HRP) conjugated anti-rabbit, mouse, or rat
secondary antibodies (Santa Cruz), and the protein bands were
developed using enhanced chemiluminescence detection (ECL; Amer-
sham Pharmacia, Little Chalfont, Buckinghamshire, UK).
2.6. Co-immunoprecipitation
Cells were solubilized in lysis buffer (RIPA buffer: 20 mM HEPES
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 1%
NP-40, 1% Sodium deoxycholate, 2 mM Na3VO4, 100 mM NaF, PMSF,
protease inhibitor cocktail). The supernatant was incubated with
various primary antibodies, such as the anti-HA, anti-CRBN, anti-
AMPK β, or anti-AMPK α1 antibodies (Invitrogen), overnight at 4 °C.The antibody–protein complexes were precipitated with equilibrated
Protein G beads (Amersham Biosciences) at 4 °C for 3 h followed by
incubation with lysis buffer at 37 °C for 15 min.
2.7. Immunocytochemistry
Primary hippocampal neurons were prepared as described [23]
from embryonic day 18 Sprague–Dawley fetal rats. Cells were ﬁxed in
4% paraformaldehyde (PFA) and 4% sucrose, permeabilizedwith 0.25%
Triton X-100, and stained with mouse anti-AMPKα1 (1:5) and rabbit
anti-rCRBN antibody (1:10), overnight at 4 °C. Oregon Green 488-
conjugated anti-mouse (Molecular Probes) and Texas Red-conjugated
anti-rabbit (Molecular Probes) antibodies were used as secondary
antibodies. Cells were visualized using confocal laser scanning
microscopy. High resolution digital images were acquired using a
60× objective and were processed in Adobe Photoshop.
2.8. In vitro binding assay
For in vitro synthesis of WT AMPKα1, the catalytic domain (1–312),
the autoinhibitory plus the β-subunit binding domain (313–548), the
constitutively active mutant (α1 T172D), and the inactive mutant (α1
D157A)were subcloned into pcDNA3.1. After conﬁrming the constructs,
theywere synthesized using the TNT couple® lysate system (Promega).
Glutathione S-transferase (GST) or GST-fused rCRBN immobilized on
Sepharose beads (3–5 μg) was incubated with 3 μL of 35[S]-labeled
proteins in TBS-T–TBT binding buffer (137 mMNaCl, 20 mMTris–Cl, pH
7.6, 0.1% Tween 20, 100 mg/ml BSA and 0.5% Triton X-100), for 2–6 h at
4 °C. Samples were washed three times with the same buffer, followed
by an additional threewashes with TBS-T. After removal of thewashing
buffer, protein complexes were eluted by boiling in 20–50 μL of 2× SDS
sample buffer (100 mMTris–Cl, pH 6.8, 4% SDS, 0.2% bromophenol blue,
20% glycerol and 200 mM β-mercaptoethanol), and then separated by
SDS-PAGE. Separated protein bands were detected by exposing the gel
to BioMaxTM X-ray ﬁlm (Kodak, Rochester, NY).
3. Results
3.1. Identiﬁcation of CRBN as a novel AMPK α1 binding protein
In order to elucidate the cellular function of CRBN, CRBN binding
partners were identiﬁed by screening a rat brain cDNA library using a
yeast two-hybrid screen. One of the candidate proteins that interacted
with CRBN was identiﬁed as the α1 subunit of AMPK. Full-length CRBN
speciﬁcally interacted with AMPK α1 in yeast (Fig. 1A). The interaction
between AMPK α1 and CRBN was further characterized using
biochemical and cell biological assays. HA-fused CRBN speciﬁcally
interacted with myc-fused AMPK α1 expressed in HEK293FT cells, as
detected by co-immunoprecipitation (Fig. 1B). The association between
endogenous AMPK α1 and CRBN was also studied in HEK293FT cells.
Immunoreactivity against CRBN was detected in protein complexes
precipitated by an antibody speciﬁc for AMPKα1 (Fig. 1C, 4th blot). The
β andγ1 subunits of AMPKwere detected in theprecipitated complexes
(Fig. 1C, 2nd and 3rd blot). We also performed reciprocal co-
immunoprecipitation experiments using an antibody speciﬁc for
CRBN. Immunoreactivity against all three subunits of AMPK, αl, β, and
γ1 was detected in the protein complexes precipitated by an antibody
speciﬁc for CRBN (Fig. 1D), suggesting that CRBN can interact with the
α1 subunit of AMPK in the presence of β and γ1. In addition,
endogenous CRBN and AMPK α1 co-localized in cultured rat primary
hippocampal neurons. Neuronal AMPKα1was detected in the cell body
and dendrites where it displayed a punctate staining pattern (Fig. 2A).
Punctate staining of CRBN was also found throughout the cell body and
dendrites of hippocampal neurons (Fig. 2B), as previously shown [2]. As
illustrated in Fig. 2C, some AMPK α1 co-localized with CRBN in rat
hippocampal neurons (arrowheads).
Fig. 1. Interaction of CRBN and AMPK α1. (A) Interaction between CRBN and AMPK α1 in yeast. The full-length CRBN and AMPK α1 were simultaneously co-transformed into the
yeast strain AH109 and grown on SD/W–L– plates. (B) HEK293FT cells were transiently co-transfected with HA::CRBN andMyc::AMPKα1 or empty vector. Cells were harvested after
24 h and CRBN was immunoprecipitated using anti-HA. Western blots of the immunoprecipitates were probed with either anti-Myc or anti-HA. AMPK α1 and CRBN were detected at
approximately 72 and 53 kDa, respectively. LC indicates the IgG light chain. The plus andminus symbols indicate the presence or absence of each protein. (C) Co-immunoprecipitation of
endogenous CRBNwith the endogenous AMPKα1 fromHEK293FT cell lysates. HEK293FT cell lysateswere solubilizedwith RIPA buffer and immunoprecipitatedwith eithermouse IgG or
mouse anti-AMPK α1. The precipitates were separated by SDS-PAGE and immunoblotted with anti-CRBN, anti-AMPK α1, anti-AMPK β, and AMPK γ1. LC indicates the IgG light chain.
(D) Co-immunoprecipitation of endogenous AMPK α1 with endogenous CRBN from HEK293FT cell lysates. HEK293FT cell lysates were solubilized with RIPA buffer and
immunoprecipitatedwith either rabbit IgGor rabbit anti-CRBN. Theprecipitateswere separatedbySDS-PAGEand immunoblottedwithanti-CRBN, anti-AMPKα1, anti-AMPKβ, andAMPK
γ1. LC indicates the IgG light chain.
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Next, we asked whether CRBN interacted directly with AMPK α1
and, if so, whether the binding of these two proteins was inﬂuenced by
thephosphorylation state of AMPKα1. AMPKα1 canbephosphorylatedFig. 2. Colocalization of CRBN and AMPK α1 in hippocampal neurons. Neurons cultured for 1
and the expression patterns were visualized using a confocal microscope. AMPKα1, CRBN, an
indicate co-localized AMPK and CRBN. Scale bar: 20 μm.at Thr172 by two different AMPKK, the tumor suppressor kinase LKB1,
and the Ca2+/calmodulin-dependent protein kinase kinaseβ (CaMKKβ)
[24,25]. Phosphorylation of the Thr172 residue is amajor determinantof
AMPK α activity and we therefore included the constitutively active
AMPKα1mutant (T172D) and an inactive AMPKα1mutant (D157A) in4 days in vitrowere double stained with speciﬁc antibodies against CRBN and AMPK α1,
dmerged images are pseudocolored in green, red, and yellow, respectively. Arrowheads
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and puriﬁed by afﬁnity chromatography. The wild-type (WT) and
mutant AMPK α1 were radio-labeled using 35[S]-Met in a coupled
transcription/translation reaction in vitro. Binding assays were per-
formedby incubating [35S]-labeledWT, T172D, orD157AAMPKα1with
either GST-CRBN or GST alone immobilized on glutathione beads. All
three AMPKα1 (WT, T172D and D157A) were pulled down speciﬁcally
byGST-CRBN(Fig. 3A), suggesting that the twoproteins interact directly
and that the phosphorylation of AMPKα1 at T172 is not required for the
association between CRBN and AMPK.
In order to identify the AMPK α1 domain that interacts with CRBN,
fragments from the N-terminal region (residues 1–312) containing the
kinase domain, and a C-terminal region (residues 313–548) harboring
the AID and theβ-subunit binding domainwere generated.While CRBN
bound to both fragments, the C-terminal region appeared to interact
with CRBNwith higher afﬁnity than theN-terminal region (Fig. 3B).We
further narrowed down the CRBN-interacting regions of AMPK α1 by
constructing eight different deletion mutants (Supplemental Fig. 2A).
It was shown by in vitro binding assay that two different regions, α1
(1–100) at the N-terminal end and α1(393–473) in the C-terminal
region, interacted with CRBN (Supplemental Fig. 2B). By comparing
the results of three different constructs, α1(313–422), α1(423–548)
and α1(393–473), we were able to show that a small region in the
C-terminus covering the amino acid 393–422would be critical for high-
afﬁnity binding to CRBN. It was worth noticing that the N-terminal end
of AMPK α1 was predicted to locate closely with the C-terminal region
covering the residue393–473 in a recent structuralmodel [27]. Since the
C-terminal β-subunit binding domain of the AMPKα1 subunit is critical
for interactionwith theβ subunit and theC-terminal regionof theAMPKFig. 3. Disruption of the interaction between the α and γ subunit of AMPK by CRBN. (A) G
panel, lanes 2, 5, 8 and 3, 6, 9), respectively. The wild-type (WT), constitutively active mut
pcDNA3 vector, transcribed to mRNA, and then translated in vitro using the TNT couple® lysa
or absence of each protein. (B) Full-length protein (1–548), N-terminal fragment [residue
domain (AID) and β-subunit binding domain of AMPKα1] were obtained as described in (A)
or pcDNA3-HA/CRBN. Proteins were precipitated with anti-AMPK α1 and probed with anti-
expressed HA-CRBN were detected at approximately ~68, 38, 37, and 53 kDa, respectiv
densitometric analysis of the blot in (C). The results shown are the means±SD of four indeα1 contains a regulatory sequence (RS) that is located close to the γ
subunit [27], the binding of CRBN to the C-terminal region of the AMPK
α1 (residues 313–548) may affect formation of the AMPK complex
madeupofα,β andγ subunits. Thus,weexaminedwhether anexcessof
CRBN could inﬂuence the formation of the AMPK complex. Since AMPK
holoenzymes exist as heterotrimeric complexes [28], the formation of
endogenous AMPK complexes was examined by immunoprecipitation
in HEK293FT cells (Fig. 3C). In eukaryotic cells, AMPK is predominantly
composed of α1βγ1 subunits [7,29]. While the band intensity of the
AMPK γ1 subunit was signiﬁcantly reduced by exogenous expression of
HA-tagged CRBN, no such decrease in band intensity was observed for
the β subunit. Moreover, HA-tagged CRBN was clearly detected in the
AMPKα1 immunoprecipitate. The intensity of theγ1 subunit relative to
theα1 subunit was reduced by approximately 60% in response to CRBN
expression, but no signiﬁcant change in the intensity of the β subunit
was observed (Fig. 3D). The decreased intensity of the γ subunit in the
presence of CRBN was also evident when the AMPK complex was
precipitated using the antibody speciﬁc for theβ subunit (Supplemental
Fig. 3). Together with the data showing the binding of CRBN to the
C-terminal region of AMPK α1 in vitro, these results strongly suggest
that CRBN can reduce the afﬁnity of the γ1 subunit for the AMPK
complex by directly binding to the α1 subunit.
3.3. Suppression of AMPK activation by ectopic expression of CRBN
Theγ subunit of AMPK is a sensor that detects increased levels of AMP
evoked by energy imbalance [15,30]. Thus, dissociation of the γ subunit
from the AMPK complex by CRBN may inﬂuence AMPK activity in
energy-restricted conditions. To examine the effect of CRBN expressionST and GST-CRBN were detected at approximately ~26 kDa (*) and 79 kDa (**) (upper
ant (T172D), and inactive mutant (D157A) AMPK α1 were subcloned into a modiﬁed
te system (Promega) with [35S]-Met. The plus and minus symbols indicate the presence
s 1–312, kinase domain], and C-terminal fragment [residues 313–548; autoinhibitory
. (C) Cell lysates were prepared from HEK293FT cells transfected with pcDNA3-HA (HA)
AMPK α1, anti-AMPK β, anti-AMPK γ1, and anti-HA. Endogenous AMPK α1, β, γ1, and
ely. LC indicates the IgG light chain. (D) Relative band intensity was measured by
pendent experiments.
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pcDNA3-HA or pcDNA3-HA/CRBN, using CRBN sequences from human,
mouse or rat. The intensity of the phosphorylated AMPK α1 (phosphor-
AMPK α1) band, which indicates the level of activation of the enzyme,
was signiﬁcantly decreased by exogenous expression of each of the CRBN
genes, compared to mock (pcDNA3-HA) transfected cells (Fig. 4A). The
level of AMPK α1 activation was compared by quantifying the ratio of
phosphorylated AMPK α1 to total AMPK α1 (P-AMPK α1/AMPK α1)
(Fig. 4B). Expressionofhuman,mouse, and ratCRBNdecreased theAMPK
activation by 46%, 42%, and 42%, respectively (Fig. 4A and B). We also
examined the effects of rat CRBN expression in three different neuronal
cell lines. The pcDNA3-HA or pcDNA3-HA/CRBN constructs were
transiently transfected into human neuroblastoma SH-SY5Y, mouse
hippocampal HT22, and rat neuroblastoma B103 cells. Western blot
analyses revealed that the band intensity of phosphor-AMPK α1 was
signiﬁcantly reduceduponectopic expressionofHA-CRBN inall three cell
lines tested (Fig. 4C). The relative band intensity of P-AMPKα1/AMPKα1
was decreased by 44% in SH-SY5Y, 56% in HT22, and 41% in B103 cells
(Fig. 4D). These results indicate that ectopic expression of CRBN can
inhibit the activation of AMPK indiverse cell types and that the inhibitory
effects of CRBN from three different species are comparable.
The effects of CRBN expression under conditions known to activate
endogenous AMPK were examined. AMPK can be activated by
chemical activators, such as AICAR, or by serum starvation [31,32].
Activation of AMPK, as indicated by the phosphorylation of AMPK α1,
was detected in HEK293FT cells in response to serum starvation alone
or in combination with AICAR treatment (Fig. 5A). To evaluate the
effects of CRBN on AMPK activation in response to serum starvation,
HEK293FT cells that had been transiently transfected with pcDNA3-
HA or pcDNA3-HA/CRBN were incubated under serum-deprived
conditions for 24 h. In control cells transfected with pcDNA3-HA, a
signiﬁcant increase in the phosphorylation of AMPK α1 was observedFig. 4. Decreased AMPK activation in cells expressing CRBN. (A) HEK293FT cells were transie
mouse, or rat origin, respectively. Proteins were separated on SDS-PAGE and immunoblotted
equal protein loading. (B) To determine the effects of CRBN expression on AMPK activat
densitometric analysis of the blot in (A). The results shown are the means±SD of four ind
HT22 cells, and rat neuroblastoma B103 cells were transfected with pcDNA3-HA (Mock) or p
using anti-phosphorylated-AMPK α1 and anti-HA. Anti-AMPK α1 was used to probe for e
analysis of the blot in (C) to determine the effects of CRBN expression on AMPK activatio
independent experiments.in response to serum starvation (Fig. 5B, lanes 1 and 3, 2nd panel).
However, the expression of CRBN potently inhibited phosphorylation
of the α1 subunit, both in the presence and the absence of serum
(Fig. 5B, lanes 2 and 4, 2nd panel). The effects of CRBN expression on
AMPK activation in the absence or presence of serum are summarized
in Fig. 5C. The ectopic expression of CRBN decreased the relative
intensity of phosphor-AMPK α1 by 43% under normal culture
conditions and by 34% under serum-deprived conditions. We also
examined the effects of CRBN on the downstream AMPK signaling
pathway. The reduction in AMPK α1 activation resulted in the
suppression of phosphorylation of the acetyl coenzyme A carboxylase
(ACC), a well characterized AMPK substrate (Fig. 5B, lanes 2 and 4, 4th
panel). The level of ACC phosphorylation was compared in the
presence or absence of CRBN expression by quantifying the ratio of
phosphorylated ACC to total ACC (P-ACC/ACC). Ectopic expression of
CRBN decreased the relative intensity of P-ACC by 48% under normal
culture conditions and by 36% under serum-deprived conditions
(Fig. 5D). These results indicate that overexpression of CRBN
decreases the phosphorylation of AMPK α1 and, thus, suppresses
AMPK activity in a serum-independent manner.
3.4. Up-regulation of AMPK activity by knockdown of endogenous CRBN
Although AMPK activity was clearly suppressed by the ectopic
expression of CRBN, it was unclear whether endogenous CRBN
regulated AMPK activity. We therefore examined the regulation of
AMPK signaling in the HT22 cell line, in which endogenous CRBN was
suppressed by stable expression of an shRNA speciﬁc for CRBN.
Western blotting was used to conﬁrm the suppression of endogenous
CRBN at the protein level (Fig. 6A). Moreover, we conﬁrmed that the
expression level of endogenous LKB1 and CaMKKβ in the CRBN
knockdown (KD) cell line was not signiﬁcantly different from that inntly transfected with pcDNA3-HA (Mock) or pcDNA3-HA/CRBN (HA::CRBN) of human,
with anti-phosphorylated-AMPK α1, and anti-HA. Anti-AMPKα1 was used to probe for
ion in total and phosphorylated AMPK, the relative band intensity was measured by
ependent experiments. (C) Human neuroblastoma SH-SY5Y cells, mouse hippocampal
cDNA3-HA/CRBN (HA::CRBN), respectively. Proteins were subjected to immunoblotting
qual protein loading. (D) The relative band intensity was measured by densitometric
n in total and phosphorylated AMPK. The results shown are the means±SD of four
Fig. 5. Effects of exogenousCRBNonAMPKactivationby serumdeprivation. (A)HEK293FT
cells grown in the presenceor absenceof serumwere incubated in thepresenceor absence
of 1 mMAICAR for 24 h.Western blot analysiswas performedwith anti-AMPKα1 (or anti-
phospho-AMPK α1). Anti-AMPK α1 was used to probe for equal protein loading. (B) Cell
lysates were prepared from HEK293FT cells transfected with pcDNA3-HA (HA) or
pcDNA3-HA/CRBN (HA::CRBN). Proteins were subjected to immunoblotting using anti-
phospho-AMPK α1 and anti-ACC. Anti-AMPK α1 and anti-ACC were used to probe for
equal protein loading. Endogenous AMPK α1 (or phospho-AMPK α1), ACC (or phospho-
ACC), and expressed HA-CRBN were detected at approximately ~63, 260, and 53 kDa,
respectively. Theplus andminus symbols indicate the presence or absence of eachprotein.
(C) Relative band intensity of was determined by densitometric analysis of (B). The results
shown are the means±SD of four independent experiments.
Fig. 6. Increase in AMPK activation by suppression of endogenous CRBN. (A) CRBN
knockdown cell lines were generated by infecting mouse hippocampal HT22 cells with
a lentivirus carrying a short hairpin RNA (shRNA). Lysates were immunoblotted with
rabbit anti-CRBN. Anti-GAPDH was used to probe for equal protein loading. (B) CRBN
knockdown cells were grown in the presence of serum for 24 h and, subsequently, in
the absence of serum for 3 h. Cells were then washed with HBSS three times and
incubated for the indicated times (10, 30, and 60 min) in HBSS. (C) Relative band
intensity of was determined by densitometric analysis of the blot in (B). The results
shown are the means±SD of four independent experiments.
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nutrient-free medium (Hank's buffered salt solution, HBSS), as
described previously [33], phosphorylation of AMPK α1 slightly
increased, in a time-dependent manner, in control cells expressing a
scrambled shRNA. In contrast, AMPK activation was dramatically
increased, by up to seven-fold, in the CRBN knockdown (KD) cell line
within 60 min (Fig. 6C). These results further support the hypothesis
that CRBN can function as an endogenous repressor of AMPK activity.
4. Discussion
AMPK is a multifunctional metabolic sensor that maintains cell
survival in human diseases associated with metabolically abnormal
conditions [34]. However, the mechanisms that regulate AMPK in vivo
are still poorly understood. By searching for proteins that bind CRBN,
we demonstrated that CRBN directly interacts with the α subunit of
AMPK and reduces the enzymatic activity of AMPK by suppressingphosphorylation of its catalytic subunit. The interaction between
AMPK α1 and CRBN was conﬁrmed in vivo as well as in vitro and the
binding of CRBN reduced the level of the γ subunit in the AMPK
complex (Fig. 3C), suggesting its potential role as an endogenous
negative modulator.
We observed that the activation of endogenous AMPK is greatly
enhanced in CRBN KD cells (Fig. 6C) further implies that at least some
CRBN may be present in the endogenous AMPK complex as a binding
partner and limit the activation of AMPK. Under nutrient-reduced
conditions, CRBN KD cells exhibited a faster and more substantial
activation of AMPK, with a 2-fold increase at 10 min and a 7-fold
increase at 60 min, compared to the control cells, which exhibited a 2-
fold increase at 30 min and a 3-fold increase at 60 min (Fig. 6C).
Negative regulation by CRBNmay block the hyper-activation of AMPK
in both presence and absence of sufﬁcient nutrients. One possible
interpretation is that CRBN may interfere with the ﬂexibility of the
AMPK complex, potentially affecting the interaction between the RS
(regulatory sequence) with a neighboring sequence of α subunit and
γ subunit. Although the X-ray structures of AMPK complex were
revealed recently by three independent groups [9,15,16], the structures
454 K.M. Lee et al. / Biochimica et Biophysica Acta 1813 (2011) 448–455did not include the kinase domain of the α subunit or the N-terminal
region of the β subunit. One of structural studies showed that an
interaction was possible between the RS of the α subunit and the γ
subunit [16]. It was conﬁrmed in a separate study that the RS of the α
subunit is indeed near the AMP-binding site (Site 1) of the γ subunit
[27]. Basedon these recent structural studies, it is possible that Thr172 is
better protected fromdephosphorylation in the absence of CRBN than in
its presence, because CRBN interacts with the AMPK α1 subunit via
separate binding sites in the N-terminal and C-terminal regions
(Fig. 3B). This idea is supported by the fact that CRBN interacts strongly
with AMPK α1 via a C-terminal region covering amino acid 394–422
(Supplemental Fig. 2B) and that this CRBN-interacting region is co-
localized [27] or very close to the RS [8]. Alternatively, CRBN could
interfere with the stability of the AMPK complex and cause the
dissociation of the γ subunit, especially when CRBN is overexpressed.
Dissociation of the γ subunit may have implications for the suppression
of AMPK activity, since the AMP-binding γ subunit could induce a
conformational change in the kinase domain of the α subunit that
protects AMPK from Thr172 dephosphorylation [27]. Thus, the direct
bindingof CRBN to theα subunit and the liberation of theγ subunit from
the AMPK complex may result in suppression of enzymatic activity and
lack of phosphorylation of downstream targets such as ACC (Fig. 5B).
Initially, the CRBN gene was identiﬁed in a group of ATNSMR
patients as having a single C to T point-mutation at position 1274 [1].
This nonsensemutation is likely to cause premature termination and a
deletion of the last 24 amino acids of human CRBN. However, the
molecular pathology of the CRBN mutation remains elusive. To our
knowledge, there are no reports clearly showing the expression of a
truncated CRBN in affected individuals. It will be of interest to ﬁnd out
whether the inhibitory effects of CRBN on AMPK are modiﬁed by the
mutation in ATNSMR patients. Since CRBN interacts with the α1
subunit of AMPK via its N-terminal Lon domain (Supplemental Fig. 5),
it remains to be seen whether the truncated CRBN missing the C-
terminal 24 amino acids exhibits any differences in binding to the
AMPK α1 subunit and suppression of AMPK activity.
In a recent report, CRBN was characterized as a substrate binding
component of the E3-ubiquitin ligase and aprimary target of thalidomide
teratogenicity [4]. SinceAMPKα1 interacts directlywithCRBN, theAMPK
α1 subunit may be a previously unidentiﬁed substrate for the CRBN E3
ubiquitin ligase. However, the subcellular location of AMPK α1 differs
from the CRBN E3 ubiquitin ligase complex. While AMPK α1 is located
throughout the cytoplasm and the nucleus [35,36], themajority of the E3
complex containing DDB1 (damaged DNA-binding protein 1) and Cul4
(Cullin 4) is found in the nucleus [37]. Notably, the nuclear localization of
CRBN as a component of the E3 ligase complex was conducted only with
exogenous CRBN [4]. In addition, according to previous reports [2,3,38],
most of the immunoreactivity against endogenous CRBN is found in the
cytoplasm, including the soluble and light membrane fractions, in three .
Thus, whether CRBN plays a role in many different cellular functions, as
do many other substrate binding components of the E3 ubiquitin ligase
[39–42], remains to be determined.
As a key sensor of metabolic stress, AMPK has been associated with
many humandiseases.Whilemany researchers have suggested that the
activation of AMPK protects cells from hypoxic/ischemic damage [32],
several reports revealed opposing roles for AMPK in the induction of
oxidative stress and neuronal death in stroke [43,44]. The AMPK
signaling cascade may differ depending on the upstream activating
kinase, such as LKB1 or CaMKKβ [25,45]. Thus, the protective or
suppressive effects of CRBN in human metabolic diseases remain an
intriguing possibility. The suppression of AMPK activity by CRBN may
provide a valuable link between the cellular function of this novel
protein and the pathology of the human mutation. In conclusion, CRBN
may negatively regulate the functional activity of AMPK in vivo by
binding directly to its α1 subunit.
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